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Background: A decrease of small nerve fibers in skin biopsies during the course of critical illness has been
demonstrated recently. However, the diagnostic use of skin biopsies in sepsis and its time course is not known.
Methods: Patients (n=32) with severe sepsis or septic shock were examined using skin biopsies, neurological
examination, nerve conduction studies, and sympathetic skin response in the first week after onset of sepsis,
2 weeks and 4 months later and compared to gender- and age-matched healthy controls.
Results: Skin biopsies at the ankle and thigh revealed a significant decrease of intraepidermal nerve fiber density
(IENFD) during the first week of sepsis and 2 weeks later. All patients developed critical illness polyneuropathy (CIP)
according to electrophysiological criteria and 11 showed IENFD values lower than the 0.05 quantile. Four patients
were biopsied after 4 months and still showed decreased IENFD. Results of nerve conduction studies and IENFD did
considerably change over time. No differences for survival time between patients with IEFND lower and larger than
3.5 fibers/mm were found.
Conclusions: Skin biopsy is able to detect an impairment of small sensory nerve fibers early in the course of sepsis.
However, it may not be suited as a prognostic parameter for survival.
Trial registration: German Clinical Trials Register, DRKS-ID: DRKS00000642, 12/17/2010
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Severe sepsis and septic shock represent the third lead-
ing cause of death in industrialized countries [1, 2] and
are among the most challenging conditions in modern
medicine. A particularly harmful complication of sepsis
is ICU-acquired weakness (ICUAW) [3, 4]. ICUAW may
be caused by muscle wasting [5], critical illness poly-
neuropathy (CIP), critical illness myopathy (CIM), or as
in most cases, a combination of CIP and CIM [6]. About
70 % of patients with sepsis [7], and up to 100 % of pa-
tients with multi-organ failure develop CIP [8], but this
may be an overestimation due to use of different diag-
nostic criteria between studies [9]. Development of CIP
is associated with increased mortality, prolonged times on
the respirator, and longer rehabilitation periods [10–12].* Correspondence: hubertus.axer@med.uni-jena.de
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(http://creativecommons.org/publicdomain/zeCIP and CIM share the major clinical signs comprising
symmetric and flaccid weakness of the muscles and the
absence of deep tendon reflexes [13]. Patients with CIP
also have distal loss of sensitivity to pain, temperature,
and vibration. Nerve conduction studies detect CIP and
CIM early during the first week of the disease [14, 15].
Typical signs of CIP and CIM are reduction in the
amplitude of compound muscle action potentials, whilst
nerve conduction velocity is mainly preserved. In CIP,
amplitudes of sensory nerve action potential (SNAP) may
also be reduced or missing, indicating axonal damage to
sensory nerves [16, 17].
In recent years skin biopsy has become a valuable tool
for the evaluation of patients with small nerve fiber
pathological change [18, 19], with reliable normative
data [20]. Skin biopsy obtained using a disposable 3-
mm-diameter punch is minimally invasive and generally
safe [21]. Skin biopsy is typically taken at the ankle and/
or the thigh. The tissue is processed histologically withdistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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can be estimated by counting the nerve fibers crossing the
basal lamina of the epidermis over the surface length of
50-μm-thick sections of the skin. Intraepidermal nerve
fiber density (IENFD) closely correlates with clinical
symptoms and is more sensitive than sensory nerve con-
duction studies and sural nerve biopsies for diagnosing
small fiber neuropathy. Diagnostic efficiency and predict-
ive values are very high using this technique [18, 22].
An impairment of small nerve fibers in sepsis may play
a major pathophysiological role in neuropathic pain syn-
dromes, which often become apparent after recovery from
severe illness and after discharge from the ICU [23]. In
addition, autonomic dysregulation plays a significant role
in the acute phase of severe sepsis [24]. Lately, the occur-
rence of CIP has been related to decreased heart rate vari-
ability [25]. It is well-known that autonomic dysregulation
is associated with increased long-term mortality rates
[26, 27]. In addition, there appears to be correlation
between IENFD and abnormal autonomic function
assessed by quantitative sudomotor axonal reflex test
in patients with painful neuropathy [28]. Therefore,
we hypothesized that impairment of small nerve fibers
plays a role as a prognostic marker in sepsis.
Latronico et al. [29] performed skin biopsies at the
ankle and thigh in 14 adult patients under neurocritical
care, who had a prolonged ICU length of stay and artifi-
cial ventilation on median ICU-day 22. All patients had
severe and non-length-dependent loss of intraepidermal
nerve fibers. Of these patients 13 had infections, sepsis
or multiple organ failure. In addition, sweat gland in-
nervation was reduced in all except one patient.
In another study [30], IENFD of the distal leg was
assessed on admission to the ICU and 10–14 days later.
Of the 11 patients recruited, 9 (82 %) had sepsis or mul-
tiple organ failure. Median IENFD on admission decreased
significantly. Abnormal IENFD was observed in 8 patients
(72.7 %). Electrodiagnostic signs of large fiber neuropathy
and/or myopathy were found in 6 patients (54.5 %), and
autonomic dysfunction in 2 patients (18.2 %).
The aim of this study was to examine the decrease in
intraepidermal nerve fibers in CIP in the early phase of
sepsis, to describe the time course of intraepidermal
nerve fiber density at the ankle and thigh during the
course of sepsis, and to evaluate the use of IENFD as a
prognostic marker in the acute phase of sepsis.
Methods
Study design
The study protocol for this single-center, non-randomized,
controlled, observational study has been published
earlier in detail [31]. The study has been registered
with the German Clinical Trials Register (DRKS-ID:
DRKS00000642).Patients ≥18 years of age with severe sepsis and/or
septic shock according to published criteria [32] were
screened for eligibility. Exclusion criteria were: history of
neuromuscular disorders (such as polyneuropathy, my-
asthenia gravis, myopathy, and others), known alcohol
abuse, high-dose steroid therapy before sepsis (≥16 mg
prednisolone/kg body weight for 5 days or equivalent
dose of other corticosteroids), ICU stay ≥8 days, participa-
tion in another clinical study, platelet count <40 Gpt/
l(109/l), partial thromboplastin time (PTT) >60 s, inter-
national normalized ratio (INR) >1.7, or if the patient was
likely to die within less than 24 hours.
Patients admitted to the ICUs at Jena University Hos-
pital between February 2011 and April 2015 were en-
rolled in the study. Written informed consent was
obtained from all patients or their legal representatives
and from all healthy controls. The study was approved
by the Ethics Committee of the Friedrich Schiller Uni-
versity Jena (number 2771-02/10).
Baseline characteristics of the patients (e.g., underlying
disease, age, gender, body mass index, ICU characteristics,
i.e., duration of stay, length of mechanical ventilation, etc.)
were obtained from the standardized prospective sepsis
registry established at Jena University Hospital [33].
Study visits were performed between days 2 and 5 after
onset of severe sepsis/septic shock, and at 2 weeks and
4 months, with skin biopsies performed at the thigh
and ankle. Neurological examination (including the
Medical Research Council (MRC) score for muscle
strength), nerve conduction studies, and sympathetic
skin response were undertaken at each visit. Figure 1
summarizes patient flow and study visits.
In addition, gender- and age-matched healthy controls
with a normal neurological status were visited once and
skin biopsies were taken from the right ankle and thigh.
The age of the matched control was not permitted to
differ by more than 2 years from the age of the consecu-
tive patient. As the controls were required to be healthy
(including the older individuals) exclusion criteria were
defined as: diabetes mellitus, history of neuromuscular
disorders (such as polyneuropathy, myasthenia gravis,
myopathy, and others), alcohol abuse, infection, history
of cancer, coagulopathy, or contraindication to local an-
esthetics. Healthy controls were recruited in the local
sport clubs to specifically include healthy people of dif-
ferent ages.
Nerve conduction studies
Standardized nerve conduction studies were carried out
at each visit using a portable electrophysiologic device
(Synergy 15.0; Natus Europe GmbH, Planegg, Germany)
with surface electrodes, according to standard proce-
dures described in the literature [34]. The right median
nerve, the right tibial nerve, the left peroneal nerve, and
Fig. 1 Study flow
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nerve responses were assessed for the right median
nerve, motor responses only for the tibial and fibular
nerves, and sensory nerve responses for both sural
nerves. This pattern was chosen for pragmatic reasons
to guarantee a fast and easy electrophysiological check-
up: three motor and three sensory measurements of the
arm and both legs were obtained.
Sympathetic skin responses evoked by electrical
stimulation of the median nerve were measured at
the hands and feet as a neurophysiological equivalent
of autonomic nerve function. Active surface electrodes
were placed on the palmar side of the hands and the
plantar side of the feet with reference electrodes on
the dorsum of the hands and feet. An electrical stimulus
(20–30 mA, 0.2 ms, with an irregular interval) was given
to the right median nerve at the wrist. Skin potentials
were recorded for a 10-s analysis period at both hands and
feet. Sympathetic skin response was considered absent if
there was no response after four stimuli.
Electrophysiological measurements were performed
by experienced technical assistants from the neuro-
physiological department. Normative values for selectedconduction study parameters derived from our own
laboratory were used. Normative values were adjusted to
age (e.g., 3.8 μV for older age), as sural nerve SNAP is
often much lower in older healthy individuals.
Skin biopsies
Skin biopsies were taken from the right ankle and thigh
at each visit using a 3-mm biopsy punch and were
immediately fixed in Zamboni's solution (2 % parafor-
maldehyde and picric acid) for approximately 24 h at
4 °C, then kept in a cryoprotective solution, and seri-
ally cut with a freezing microtome into 50-μm-thick
sections. The sections were immunostained with anti-PGP
9.5 antibodies (anti protein gene product 9.5 antibody,
ab72911, Abcam, Cambridge, UK) to label small nerve fi-
bers in the skin and were counterstained with hematoxylin
and eosin. Bright field microscopy for routine diagnostic
purposes was used to count intraepidermal nerve fiber
density (IENFD) defined by the number of stained
nerve fibers crossing the basal lamina of the skin
divided by the length of the epidermal surface. Image J
1.47v (National Institutes of Health, USA) was used for
image processing [35].




Age, years, median, mean (IQR) 69, 67.41 (61.50–77.25)
Male gender, number (%) 19 (59.4)
Body mass index, kg/m2, mean ± SD 27.50 ± 5.04
Clinical data
APACHE II scorea, mean ± SD 23.38 ± 5.73
Septic shock, number (%) 25 (78.1)
History of diabetes, number (%) 13 (40.6)
Heart failure, number (%) 5 (15.6)
Cerebrovascular disease, number (%) 15 (46.9)
Renal dysfunction, number (%) 3 (9.4)
Chronic obstructive pulmonary disease,
number (%)
4 (12.5)
Liver cirrhosis, number (%) 0 (0.0)
History of cancerb, number (%) 2 (6.3)
Immunosuppressionc, number (%) 4 (12.5)
Recent surgical history
Elective surgery, number (%) 2 (6.3)
Emergency surgery, number (%) 8 (25.0)
No history of surgery, number (%) 22 (68.8)
Site of infection (multiple responses per patient possible)
Pneumonia, number (%) 20 (62.5)
Other respiratory tract, number (%) 3 (9.4)
Intraabdominal/gastrointestinal, number (%) 6 (18.8)
Bones/soft tissue, number (%) 0 (0.0)
Surgical wound infection, number (%) 0 (0.0)
Urogenital, number (%) 1 (3.1)
Primary bacteremia, number (%) 1 (3.1)
Cardiovascular, number (%) 1 (3.1)
Others (central nervous system, thoracal,
catheter, etc.), number (%)
4 (12.5)
Source of infection
Community acquired, number (%) 9 (28.1)
Nosocomial, number (%) 23 (71.9)
Infection
Microbiologically confirmed, number (%) 27 (84.4)
Clinical evidence, number (%) 5 (15.6)
Mortality, length of stay, mechanical ventilation, renal replacement
ICU mortality, number (%) 2 (6.3)
Hospital mortality, number (%) (95 % CI) 5 (15.6) (6.86; 31.75)
Length of stay on ICU, calendar days,
median (IQR)
24.5 (17–30.25)
Length of stay in hospital, calendar days,
median (IQR)
29 (24–48.5)
Mechanical ventilation, number (%) 31 (96.9)
Table 1 Demographics and baseline characteristics of patients
(n = 32) (Continued)
Days with mechanical ventilationd,
median (IQR)
20.5 (14–29)
Renal replacement therapy, number (%) 5 (15.6)
Days with renal replacement therapy,
median (IQR)
18 (18–20)
aMissing subscores counted as 0. bAt least one of leukemia, hematologic
malignancy and malignant lymphoma. cAt least one of cytostatic therapy,
radiation, immunosuppression and steroids. dIf not mechanically ventilated,
counted as 0 days. APACHE Acute Physiology and Chronic Health Evaluation
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by two trained raters (HA and SB) blinded for the as-
signment of the probe to either patient or control group.
Intra-rater intraclass correlation coefficients (ICC) for
estimation of IENFD were 0.977 at the ankle and 0.927
at the thigh. Inter-rater ICCs for estimation of IENFD at
the ankle were 0.927 and 0.844 at the thigh. Data were
reported from the first rater (HA). IEFND values were
regarded as significantly reduced if they were lower than
the 0.05 quantile per age span and gender according to a
worldwide normative reference study [20].
Statistics
IBM SPSS Statistics Version 19 (SPSS Inc., Chicago, IL,
USA) and R Version 3.1.0 [36] were used for statistical
analysis. Descriptive statistics were used to characterize
demographic data, baseline characteristics of the patients,
and major parameters of nerve conduction studies such as
amplitudes and conduction velocity. The unpaired t test
was used with a two-sided significance level of 5 % to
compare IENFD between groups. Kaplan–Meier curves
and the log-rank test were used to analyze the use of
IENFD at the ankle in the first week of sepsis as a possible
prognostic factor for survival.
Results
The demographic data of our study population are pre-
sented in Table 1. 313 patients were screened, but in
many cases (18 %) the patients’ legal representatives did
not approve participation in the study, mainly due to the
invasive character of skin biopsy. Exclusion criteria were
met in 185 patients (59 %), essentially the existence of
polyneuropathy, alcohol abuse, or coagulopathy. A total
of 32 patients, who fulfilled the criteria for severe sepsis
or septic shock, were biopsied in the first week after on-
set of sepsis. Healthy controls (n = 32) with normal
neurological status were matched to the sepsis patients
according to age and gender (19 male and 13 female in-
dividuals in both groups, mean age 66.75 years, median
age 71.5 years, IQR 60.5–75.0 in the control group).
Healthy controls did not have any metabolic disease
(such as diabetes mellitus), neuromuscular disease, or
alcohol abuse. They only had comorbidities that do not
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coronary heart disease (n = 2), lower back pain (n = 2),
depression (n = 1), and history of basal cell carcinoma
that had been completely excised and cured (n = 1)).
All sepsis patients had CIP according to electro-
physiological criteria. CIP was diagnosed, when am-
plitudes of compound muscle action potential and
sensory nerve action potential [17, 37] were reduced
in at least three nerves. Electrophysiological diagnosis
of CIP was not based on pathological sural nerve
potential alone as these may be notably susceptible to
edema. Clinically, all patients suffered from muscle
weakness (see Additional file 1). However, the major-
ity of patients received analgo-sedation and mechan-
ical ventilation (25 patients (78.1 %) with mechanical
ventilation at first visit). None of the patients were
exposed to high-dose steroids (exclusion criteria of
the study) or neuromuscular blocking agents. No pa-
tient suffered from HIV. All patients received passive
or active physiotherapy.
Nerve conduction studies displayed changes typical
of axonal damage during the first week after onset of
sepsis. Reductions in amplitudes of motor and sensory
action potential were more pronounced than reduc-
tions in conduction velocity. Electrophysiological pa-
rameters did not change significantly over the time
course of sepsis (see box plots of amplitudes of action
potential and conduction velocity in Additional file 2).
The sympathetic skin response at the hands and feet
was lost in all patients.Fig. 2 Example of histology of skin biopsies in septic patients (a and c) and
considerably decreased in septic patients. Arrows show examples of nerveSkin biopsies (Fig. 2) revealed a considerable decrease
in small nerve fibers in the septic patients early in the
course of disease. Eleven of the patients (34 %) showed
IEFND values lower than the 0.05 quantile per age span
and gender according to a worldwide normative refer-
ence study [20] during the first week of severe sepsis or
septic shock. Figure 3 shows the boxplots for intraepi-
dermal nerve fiber density at the ankle and thigh of the
patients in comparison to the controls. IENFD at the
ankle and thigh were significantly decreased (p <0.0001)
in patients compared to age- and gender-matched con-
trols during the first week of sepsis (n = 32) and 2 weeks
later (n = 19). After 4 months, four patients were sub-
jected to a third skin biopsy. In these patients IEFND
was still reduced. The results were not statistically sig-
nificant (p = 0.452 at the ankle, p = 0.076 at the thigh)
due to the small sample size. The main reasons (Fig. 1)
for not obtaining follow-up skin biopsies were death and
the development of contraindications to skin biopsy,
such as anticoagulation or coagulopathy.
The ratio between IENFD at the ankle and thigh did
not differ between patients and controls (p = 0.103 at
visit 1, p = 0.113 at visit 2, and p = 0.8 at visit 3). This ratio
is an indicator of length-dependent nerve damage; it is
considerably increased if distal nerve fibers (at the ankle)
are impaired to a much greater extent than proximal
nerve fibers (at the thigh).
At the first visit only 7 of the 32 patients were evalu-
ated for sensory symptoms such as sensory loss or
dysesthesia. Mean pallesthesia was 3.7 (on a scalenormal controls (b and d). Intraepidermal nerve fiber density is
fibers
Fig. 3 Intraepidermal nerve fiber density (IENFD) in patients (sepsis) and controls over time. IENFD in patients with sepsis are significantly
decreased in comparison to age- and gender-matched controls
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sia)) with standard deviation of 3.3 measured by the use
of a tuning fork placed over the lateral malleolus. At
visit 2, there were 10 out of 19 patients evaluated: only
1 of the 10 patients complained of sensory symptoms.
The four patients examined after 4 months had mean
pallesthesia of 5.6 with standard deviation of 1.5. Three
of these patients complained of sensory symptoms.
In addition, patients with sepsis were grouped according
to the number of confounding co-morbidities for neur-
opathy (especially diabetes, history of cancer and chronic
kidney disease, Table 1). Alcohol abuse was an exclusion
criterion. IENFD at the ankle and thigh was significantly
reduced in the 17 patients without confounding comor-
bidities in comparison to the healthy controls (Fig. 4).
Patients were divided into two groups comprising
those with IEFND below, and those with IEFND >3.5
fibers/mm of skin, to test whether in the acute phase of
sepsis IENFD at the ankle is a prognostic marker for sur-
vival. On Kaplan–Meier curves there were no significant
differences in survival time in the two groups (p = 0.927,
Fig. 5). Median survival time was 444 days for patients
with an IENFD <3.5 fibers/mm and 303 days for patients
with an IENFD >3.5 fibers/mm.Discussion
Skin biopsy has become a valuable tool in the evaluation
of patients with small nerve fiber pathological changes
[21]. Skin biopsy represents a well-established, safe, easy,
and inexpensive method to quantify small sensory nerve
fibers and autonomic nerve fibers in the skin [18]. In
contrast, nerve conduction studies are not able to evaluate
the function of small nerve fibers. Damage to small nerve
fibers has recently been demonstrated in small samples of
critically ill patients [29, 30]. Small fiber pathological
change may play a role in the pathophysiology of sepsis,
e.g., in neuropathic pain syndromes, which often become
apparent after recovery from severe illness and after dis-
charge from the ICU [23]. Although sensory problems like
neuropathic pain, stocking/glove sensory loss, numbness
and pallhypesthesia were evaluated in this study, the ma-
jority of patients were not able to report these reliably in
the acute phase of sepsis. As neuropathic pain is a prob-
lem in the long-term follow up of patients with sepsis, a
study addressing this specific issue has to be planned
using longer periods of follow up.
In addition, autonomic dysregulation plays a signifi-
cant role in the acute phase of severe sepsis [24]. Lately,
the occurrence of CIP has been related to decreased
Fig. 4 Intraepidermal nerve fiber density (IENFD) over time in patients grouped according to number of confounding comorbidities for neuropathy. In
patients without any confounding comorbidities (n = 17) there was significant loss of IENFD at ankle and thigh in comparison to the healthy controls
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associated with increased long-term mortality [26, 27],
impairment of small nerve fibers may have an impact on
the prognosis of patients with sepsis.
In our study all patients suffered from CIP according
to electrophysiological criteria. All patients had loss of
sympathetic skin response in the hands and feet. The lat-
ter observation may also be influenced by catecholamine
therapy [38] and can therefore not be regarded as a se-
cure electrophysiological sign of autonomic neuropathy.
A major finding of this study is the early decrease in
IEFND during the first week of severe sepsis and septic
shock. In the present study, the ratio of IENFD at the
ankle (distal) and thigh (proximal) of patients and controls
were not length-dependent. Length-dependent axonalFig. 5 Kaplan–Meier curves for survival time in the patients grouped
according to intraepidermal nerve fiber density. Log-rank test 0.927.
Nr numberdegeneration (the so-called dying-back phenomenon) re-
sults in a typically distal-to-proximal gradient of axonal
degeneration with symmetrical and distally pronounced
neuropathic symptoms.
The reduction in intraepidermal nerve fibers in our
patients, who received the first biopsies on median day 4
after onset of sepsis, was similar to that observed by
Latronico et al. [29], who performed skin biopsies on
median ICU day 22. Skorna et al. [30] performed skin
biopsies on the admission to the ICU and 10–14 days
later. They demonstrated that IENFD decreased in 8 of
13 patients (72.7 %) after the admission to the ICU.
Although we excluded patients with known neuromus-
cular disorders such as polyneuropathy, one has to take
into consideration that 40.6 % of our patients suffered
from diabetes, which is a risk factor for peripheral nerve
damage. However, subgroup analysis showed that the 17
patients with sepsis who did not have confounding comor-
bidities for neuropathy also had decreased IENFD similar
to those patients with one confounder for neuropathy,
such as diabetes, chronic kidney disease, or history of can-
cer. To overcome this potential source of error, future
studies should be based on patients admitted to the ICU
with and without sepsis to study sepsis-specific neur-
opathy. All examinations of neuromuscular disturbance in
sepsis have their own limitations. A reliable estimation of
muscle strength in non-alert and non-awake patients is
generally not possible. In many cases temporal interrup-
tion of sedative drugs is not possible in hemodynamically
instable patients. Therefore, the MRC scores often cannot
be reliably measured in the acute phase of sepsis.
Amplitudes of compound motor action potential and
sensory nerve action potential in nerve conduction studies
(NCS) may also be reduced due to edema, which is often
a problem in sepsis. Moreover, NCS findings do not ex-
clude myopathy. As CIP and CIM often occur together
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were not performed to distinguish CIP from CIM in this
study, patients may also suffer from CIM. The difference
is also important with respect to the prognosis, because
the consequences of CIP last much longer than those of
CIM [41], in terms of persistent muscle weakness and the
development of chronic pain syndromes [29, 42]. In
addition, repetitive nerve stimulation was not performed
to rule out myasthenia-type abnormalities. Skin biopsy al-
lows direct allocation of the damage to the peripheral
nerves. It, therefore, may facilitate the differentiation be-
tween CIP and CIM. However, the study was not designed
to address this research question. Although skin biopsy is
an invasive method it causes only minimal pain using local
anesthesia. The histological work-up and analysis of the
skin biopsy takes some days, so that the result of the skin
biopsy is not directly available at the bedside, which is a
pragmatic restriction of the method.
Many of the legal representatives of the patients rejected
the participation of the patient in the study because they
feared the invasive character of skin biopsy. In addition,
the study had a high drop-out rate of patients over time
due to high mortality rates and contraindications against
skin biopsy (such as coagulopathy or anticoagulation).
Therefore, the initial target number of patients (n = 200)
as designated in the study protocol [31] was not reached
although over 300 patients were screened. However, the
extent the decrease in IENFD was much larger than ex-
pected and the results were statistically significant based
on considerably fewer patients than initially scheduled.
IEFND values did not change considerably over a longer
time course. In addition, the time course of decrease of
IEFND was similar to the time course of nerve conduction
study abnormalities. This is consistent with a predominant
axonal type of neuropathy with slow regeneration of the
nerves (about 1 mm per day) which requires long-lasting
rehabilitation. However, there are extreme biases related
to the four patients who underwent repeat biopsies at
4 months. These biases unfortunately question the value
of these results. Therefore, we cannot draw reliable con-
clusions from these results.
We also tested for IENFD in the first week of sepsis as
a prognostic biomarker for survival, because autonomic
neuropathy may cause autonomic dysregulation and
leads to increased mortality rates [25, 27]. In a follow-up
analysis of survival among our patients using the pro-
spective sepsis registry, a clear prognostic value of
IENFD at the ankle in the first week of sepsis was not be
observed. The cutoff value of 3.5 fibers/mm was arbi-
trarily chosen for practical reasons although IENFD nor-
mative values are age- and sex-dependent [20]. All 11
patients with an IEFND <0.05 quantiles per age span
and gender were included in the group with an IEFND
<3.5 fibers/mm and their survival rate did not differfrom that in the other groups. However, the sample size
may have been too small to differentiate survivors from
non-survivors. A larger study would be needed to def-
initely conclude that IEFND may not be suitable as a
prognostic parameter for survival.
Conclusions
The density of small sensory nerve fibers in the skin is re-
duced early in the course of sepsis. This reduction does
not depend on the length of the axons. The decrease in
intraepidermal nerve fibers does not considerably change
over time in the acute phase of sepsis; it is not a
good predictor for survival.
Key messages
 Skin biopsy detects impairment of small sensory
nerve fibers early in the course of sepsis
 It is not suitable as a prognostic marker for survival
 Intraepidermal nerve fiber density does not change
considerably over the first weeks of sepsis
Additional files
Additional file 1: Medical Research Council (MRC) scores of muscle
weakness over time. MRC scores of muscle strength were quantified
bilaterally in the arms and legs. Figure shows examples of different
proximal and distal movements of the limbs and MRC sum score. Note
that the majority of patients could not reliably be evaluated due to
analgo-sedation (2 patients with Richmond Agitation Sedation Scale
(RASS) < -1 in the second week and mechanical ventilation (78 % of
patients (n = 25) in the first week and 50 % (n = 9) in the second week),
so that muscle strength could only be evaluated in 7 patients in the first
week and 10 patients in the second week. In the patients examined
after 4 months there was a considerable improvement in muscle
strength, but muscle weakness was still detectable. Muscle weakness
was always symmetrical and affected both proximal and distal muscle
groups. (PDF 533 kb)
Additional file 2: Nerve conduction studies. Amplitudes of compound
potentials in motor and sensory nerves are considerably decreased, and
conduction velocity is marginally impaired. Note that nerve conduction
studies detect critical illness polyneuropathy early in the course of sepsis,
but amplitudes do not change considerably over the course of the disease.
Horizontal lines show the normative values of the measurements. (PDF 340 kb)
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care unit; ICUAW: ICU-acquired weakness; IENFD: intraepidermal nerve fiber
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Scale; SNAP: sensory nerve action potential.
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